Drug Profile
Research programme: neuropsychiatric disorder therapies - Eli Lilly and Company/PsychoGenics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; PsychoGenics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Psychiatric disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Neurological-disorders in USA
- 04 Nov 2017 No recent reports of development identified for research development in Psychiatric-disorders in USA
- 01 Feb 2008 Eli Lilly and Company and PsychoGenics enter into an additional drug discovery agreement for the treatment of neuropsychiatric disorders